The combined blockade of IL-1β and TNF-α by the intranasal instillation of 0.1% anti-IL-1β/TNF-α IgY could be a potential alternative strategy for preventing and treating allergic rhinitis. This evidence concerns the gene TNF and allergic rhinitis.